Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology.
Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients ...
Morning Overview on MSN
Japan approves stem-cell therapies for Parkinson’s and severe heart failure
Japan’s health ministry has granted conditional, time-limited authorization for two stem-cell therapies derived from induced pluripotent stem (iPS) cells, endorsing them for use based on early safety ...
Induced pluripotent stem cells (iPS cells) can be created from any tissue in the human body and possess the ability to transform into a wide range of tissues. Kobe University MARUYAMA Tatsuo and his ...
Nordot on MSN
Japan approves first iPS stem cell treatments – why Parkinson's and heart failure patients are watching anxiously
On 6 March 2026, Japan approved the world’s first iPS stem cell treatments for Parkinson’s and severe heart failure. Could ...
In reading, a bookmark tells where you stopped. Cells use bookmarks too, specific proteins that help the cell remember what collection of genes needs to be turned on again after the brief halt of gene ...
Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product It is well known that HLA homozygous iPSCs are often selected to reduce adverse immune response ...
Japan has formally approved the world’s first regenerative medical products utilizing induced pluripotent stem (iPS) cells, paving the way for use in patients as early as this summer.
PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem cells ...
Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.
Tokyo-based K Pharma Inc. and Nikon Cell Innovation Co. on Tuesday signed a basic agreement on a new clinical trial project using induced pluripotent stem (iPS) cells to treat spinal cord injuries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results